

Predicting outcomes following intervention for tricuspid regurgitation

Submission date 10/02/2025	Recruitment status Recruiting	☐ Prospectively registered ☐ Protocol
Registration date 03/04/2025	Overall study status Ongoing	☐ Statistical analysis plan ☐ Results
Last Edited 01/12/2025	Condition category Circulatory System	☐ Individual participant data ☒ Record updated in last year

Plain English summary of protocol

Background and study aims

This study focuses on a heart condition called tricuspid valve regurgitation (TR), where blood flows backward across the heart's tricuspid valve. This is a common issue, especially in patients who are at high risk for surgery and have had no treatment options until now. Severe TR is linked to higher death rates. Recently, new keyhole treatments have been developed that can fix the heart valve without surgery. These treatments include tricuspid transcatheter edge-to-edge repair (T-TEER) and tricuspid valve replacement (TTVR), collectively known as transcatheter tricuspid valve intervention (TTVI). The study aims to understand how patients respond to these treatments and to identify which patients might benefit the most.

Who can participate?

Patients with severe or greater tricuspid regurgitation who are considered suitable for transcatheter tricuspid valve intervention after a discussion with a multidisciplinary team can participate in this study.

What does the study involve?

Participants will undergo transcatheter tricuspid valve interventions for severe tricuspid regurgitation. They will have additional functional and quality-of-life assessments at the start of the study and during follow-up visits. The study will also involve invasive physiology assessments before and after treatment to understand how the treatment affects heart function. Researchers will look at the relationship between changes in heart function and changes in quality of life and physical ability.

What are the possible benefits and risks of participating?

The possible benefits include receiving a new treatment that could improve heart function and quality of life. However, there are risks, such as the potential for the heart to worsen suddenly if the leak is completely fixed, causing pressure overload. The study aims to identify markers that predict how well patients will respond to treatment.

Where is the study run from?

King's College London (UK)

When is the study starting and how long is it expected to run for?
December 2024 to March 2028.

Who is funding the study?
1. Edwards Lifesciences (USA)
2. British Heart Foundation (UK)

Who is the main contact?
Dr Benedict McDonaugh, benedict.mcdonaugh@gstt.nhs.uk

Contact information

Type(s)
Public, Scientific, Principal investigator

Contact name
Dr Benedict McDonaugh

ORCID ID
<https://orcid.org/0009-0000-0613-7647>

Contact details
St Thomas' Hospital, Westminster Bridge Road
London
United Kingdom
SE1 7EH
+44 20 7188 7188
benedict.mcdonaugh@gstt.nhs.uk

Additional identifiers

Integrated Research Application System (IRAS)
340256

Central Portfolio Management System (CPMS)
61262

Study information

Scientific Title
Predicting functional and clinical outcomes following transcatheter tricuspid valve intervention for severe tricuspid regurgitation

Acronym
PREDICT-TR

Study objectives
1. Baseline invasively measured contractility and ventricle-arterial coupling will predict functional response to Transcatheter Tricuspid valve intervention.

2. Atrial secondary tricuspid regurgitation (A-STR) will show an improvement in cardiac output over Ventricular secondary (V-STR) post-TTVI.

Ethics approval required

Ethics approval required

Ethics approval(s)

Submitted 16/12/2024, West London Research Ethics Committee (Health Research Authority, 2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 207 104 8098; westlondon.rec@hra.nhs.uk), ref: Reference number not provided

Primary study design

Observational

Study design

Multicentre observational cohort study

Study type(s)

Quality of life, Treatment, Efficacy

Health condition(s) or problem(s) studied

Tricuspid regurgitation, heart failure

Interventions

We will observe patients undergoing Transcatheter Tricuspid valve interventions for severe tricuspid regurgitation. We will perform some additional functional and quality-of-life assessment at baseline and at follow-up to try and understand which patients yield the greatest benefit from treatment. We will perform invasive physiology assessment before and after treatment to understand how the treatment affects cardiovascular physiology. We will assess the correlation between changes in invasive physiology and changes in quality-of-life and functional capacity. The overall aim of the study is to assess which baseline clinical, imaging and physiology characteristics correlate with treatment response to refine patient selection for tricuspid interventions.

Intervention Type

Other

Primary outcome(s)

1. Cardiac output measured invasively immediately before and after tricuspid intervention procedure.
2. Cardiac output measured non-invasively at baseline, the day of and <48hrs after tricuspid intervention procedure, at 12 weeks follow-up

Key secondary outcome(s)

1. Change in cardiac contractility measured invasively: measured immediately before and after tricuspid intervention procedure.
2. Change in cardiac function (ejection fraction and cardiac output) measured with non-invasive cardiac imaging: measured at baseline, the day of and <48hrs after tricuspid intervention procedure, at 12 weeks follow-up
3. Change in symptoms measured with the Kansas City Cardiomyopathy Questionnaire (KCCQ): measured at baseline and at 12 weeks follow-up

4. Change in exercise capacity measured with 6-minute walk test (6MWT) and average daily step count measured with wearable activity monitors: measured at baseline and at 12 weeks follow-up

Completion date

01/03/2028

Eligibility

Key inclusion criteria

Patients with severe or greater tricuspid regurgitation and deemed suitable for Transcatheter tricuspid valve intervention after multidisciplinary team discussion.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

18 Years

Upper age limit

110 Years

Sex

All

Total final enrolment

0

Key exclusion criteria

1. Anatomical or haemodynamic exclusion for TTVI
2. Pregnancy
3. Age <18 years
4. Congenital heart disease requiring intervention/surgery
5. Significant (>moderate in severity) non-tricuspid valvular disease
6. Another indication for cardiac surgery
7. Enrolment in other studies that may lead to deviation from either protocol

Date of first enrolment

01/03/2025

Date of final enrolment

01/03/2028

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Guy's and St Thomas' Hospitals

Trust Offices

Guy's Hospital

Great Maze Pond

London

England

SE1 9RT

Study participating centre

Royal Brompton Hospital

Sydney Street

London

England

SW3 6NP

Study participating centre

John Radcliffe Hospital

Headley Way

Headington

Oxford

England

OX3 9DU

Sponsor information

Organisation

King's College London

ROR

<https://ror.org/0220mzb33>

Funder(s)

Funder type

Industry

Funder Name

Edwards Lifesciences

Alternative Name(s)

Edwards, Edwards Lifesciences Corporation, Edwards Lifesciences Corp., Edwards Lifesciences LLC, E, ELC

Funding Body Type

Government organisation

Funding Body Subtype

For-profit companies (industry)

Location

United States of America

Funder Name

British Heart Foundation

Alternative Name(s)

The British Heart Foundation, the_bhf, BHF

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated and analysed during the current study will be available upon written request from the research team - contactable via Dr Tiffany Patterson, Consultant Cardiologist, St Thomas' Hospital, Westminster Bridge Road, London, SE1 9RT.

IPD sharing plan summary

Available on request